Market Overview

Morgan Stanley Upgrades Gilead Sciences To Overweight, Shares Rise

Share:
Related GILD
Gilead, Match Group, Biotech, Ethereum: 'Fast Money' Picks For May 14
55 Biggest Movers From Yesterday
Core Biotech Buys #16: Taking Advantage Of Weakness To Add To Conviction Ideas (Seeking Alpha)

Analysts at Morgan Stanley upgraded Gilead Sciences Inc. (NASDAQ: GILD) from undefined to Overweight.

Gilead Sciences shares have jumped 24.92% over the past 52 weeks, while the S&P 500 index has gained 13.45% in the same period.

Gilead Sciences' shares rose 1.92% to $95.59 in pre-market trading.

Latest Ratings for GILD

DateFirmActionFromTo
May 2018Morgan StanleyMaintainsEqual-WeightEqual-Weight
May 2018BarclaysMaintainsOverweightOverweight
Mar 2018BarclaysMaintainsOverweightOverweight

View More Analyst Ratings for GILD
View the Latest Analyst Ratings

Posted-In: Morgan StanleyUpgrades Analyst Ratings

 

Related Articles (GILD)

View Comments and Join the Discussion!